Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06800313 · ClinicalTrials.gov registry record · Phase 1

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Metastatic Disease, sponsored by Halda Therapeutics OpCo.

Recruiting
Registry status
Phase 1
Development phase
33
Enrollment target
11
Study locations

NCT06800313 is a Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Metastatic Disease that is actively recruiting participants, run by Halda Therapeutics OpCo. The registered enrollment target is 33 participants, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (74% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06800313, a Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Metastatic Disease, is actively recruiting participants, sponsored by Halda Therapeutics OpCo.

RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
11
Study locations

Study Summary

Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.

Conditions Studied

Prostate Cancer (Adenocarcinoma) Prostate Cancer Metastatic Disease

Interventions

  • DRUG HLD-0915

Study Locations (11)

Texas

  • NEXT Austin - Austin
  • The University of Texas M.D. Anderson Cancer Center - Houston

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Connecticut

  • Yale - New Haven Hospital - Yale Cancer Center - New Haven

Florida

  • Florida Cancer Specialists - Sarasota

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • START Midwest, LLC - Grand Rapids

New York

  • Evelyn H. Lauder Breast and Imaging Center (BAIC) - New York

South Carolina

  • Carolina Urologic Research Center, LLC - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2025-02-24
Est. Completion 2027-03
Phase Phase 1

Sponsor

Halda Therapeutics OpCo

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06800313

The ClinicalTrials.gov registry entry for NCT06800313 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (74% lower). The listed sponsor is Halda Therapeutics OpCo, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which HLD-0915 is the first listed.

NCT06800313 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Texas, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06800313 about?

NCT06800313 is a clinical study titled "A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.

What is the current status of trial NCT06800313?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-02-24. Estimated completion is 2027-03.

What conditions does trial NCT06800313 study?

This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease.

What interventions are being tested in trial NCT06800313?

The interventions under investigation include: HLD-0915 (DRUG).

Who is sponsoring clinical trial NCT06800313?

This trial is sponsored by Halda Therapeutics OpCo, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06800313 being conducted?

This trial has 11 study locations across Colorado, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer (Adenocarcinoma)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer (Adenocarcinoma)

All registered trials for this condition

Prostate Cancer Metastatic Disease

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.